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Since its first identification as a transformation-associated protein, osteopontin (OPN) has been recognised as important in the
processes of tumorigenicity and metastasis. Here, we review the evidence that OPN might be considered as a candidate prognostic
marker in human cancer. In animal systems, evidence from cell injection experiments and genetically manipulated mice suggest an
important but complex role for the protein in tumour progression. Moreover, studies in a variety of human cancers associate high
levels of OPN expression in tumours or in blood with more advanced cancers. The mechanism of action of OPN in promoting
cancer is still unclear, and we consider aspects of OPN biology that can complicate interpretation of human studies. Nevertheless,
growing evidence supports a role for OPN as a potential prognostic factor for various human cancers.
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The first description of the protein that would eventually come to
be known as osteopontin (OPN) was as a marker of transformation
of epithelial cells (Senger et al, 1979). Thus it is appropriate that 25
years on, there is considerable interest in the role of OPN in
human tumorigenesis, both as a marker of malignancy as well as a
candidate for testing as a prognostic factor. In this review, we
consider the current evidence for both these roles as well as
evidence from both animal models and in vitro experiments
supporting the idea that OPN acts to facilitate tumour develop-
ment.
OPN FUNCTION
In the two and a half decades since its initial description, OPN
protein or mRNA has been identified in a series of independent
biological models. Most notably, its identification as a key
noncollagenous bone matrix protein earned it the name osteo-
pontin, but the protein has also been shown to have an important
role in diverse systems ranging from the immune system, where
OPN regulates cytokine production and cell trafficking, to the
vascular system, where it inhibits ectopic mineralisation and
macrophage accumulation (Rittling et al, 2003). The protein is
secreted, variably phosphorylated and accumulates in bodily
fluids; its strong affinity for hydroxyapatite leads to its accumula-
tion in bone and other sites of mineralisation. While much of the
molecule appears to lack secondary structure, a central region
contains sequences that bind to as many as seven different
integrins, including avb3 and b5, and a series of b1-containing
integrins: the protein has a cryptic a9b1 site that is functional only
after protease cleavage, implying a unique role for OPN fragments
(Yamamoto et al, 2003). Osteopontin interacts with cells through
these integrins as well as through CD44, while an intracellular role
for OPN has also been suggested wherein OPN binds CD44 on the
inside face of the cell membrane (Sodek et al, 2000).
In vitro studies have shown that OPN has several important
functions in cells. Early on, it was recognised that OPN had
adhesive activity, confirmed by the observation that its receptors
all mediate cell adhesion. An additional well-characterised
function of OPN is in regulating migration: not only is it
chemotactic for many cell types but also OPN-deficient cells are
hypomotile (Zhu et al, 2003), suggesting that the protein plays an
intrinsic role in migration. The protein regulates cytokine
production by macrophages, and in several diverse systems, it
has been shown to act as a survival factor (Denhardt et al, 2001).
The precise molecular mechanism of OPN’s action in different
disease states, however, remains poorly defined.
OPN in tumorigenesis: animal studies
It is clear from numerous studies in cultured cells over the last 10
years that OPN expression renders cells more tumorigenic and/or
metastatic. In antisense experiments, downregulation of OPN
expression reduced growth in soft agar, growth of injected cells as
primary tumours or experimental metastasis (eg Behrend et al,
1994; see also, Denhardt et al, 2001 for review). Recently,
downregulation of OPN was shown to reduce tumorigenicity of
HGF-transformed cells, implicating OPN in the mechanism of
transformation by HGF (Ariztia et al, 2003). In experiments
examining parallel ras-transformed 3T3 cell lines from wild-type
(WT) and OPN-deficient mice, the transformed properties of the
OPN-deficient cells were uniformly attenuated as compared to WT
(Wu et al, 2000): both growth of primary tumours arising from
cells injected subcutaneously as well as experimental metastasis
were reduced in OPN-deficient cells.
Compelling evidence on the role of OPN specifically in
metastasis came from experiments in which transfection of
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DNA fragments that induced OPN expression converted the cells
from benign tumorigenic cells to fully metastatic (review:
Barraclough et al, 1998). Interestingly, the DNA fragments
responsible for these effects did not code directly for OPN protein,
or even for any protein, rather they acted as competitors for
binding of the transcription factor TCF-4, which suppresses OPN
expression. Finally, while studies correlating elevated OPN
expression with increased malignancy of a variety of cell lines
are too numerous to list here, recently several groups have noted
elevated OPN expression associated with the metastatic phenotype
following selection and expression profiling of metastatic and
nonmetastatic variants of human breast cancer cells (Urquidi et al,
2002; Kang et al, 2003).
Experiments evaluating tumorigenesis in OPN-knockout mice
directly have yielded disparate results, possibly because OPN
expressed by normal tissues and tumours may have differential
functional effects. In a squamous carcinoma model, primary skin
tumours were larger and more malignant in OPN-deficient mice as
compared to their WT counterparts. Spontaneously arising lung
metastases were also more numerous in OPN-deficient mice as
compared to WT, but the metastases were smaller (Crawford et al,
1998). An important role for OPN expressed by host cells was
implicated in this model, as host cells in WT mice expressed
significant amounts of OPN.
On the other hand, the growth of primary mammary tumours
developing spontaneously either in transgenic mice carrying c-myc
and v-Ha-ras oncogenes expressed in the mammary gland or in
mice treated with DMBA in the presence of progesterone was
unaffected by OPN status: primary tumours developed with similar
kinetics in both WT and OPN /  mice. However, neither of these
tumours metastasised at a high enough frequency to allow an
evaluation of the effect of OPN on metastasis (Feng and Rittling,
2000; Chen and Rittling, 2003). Finally, in an experimental
metastasis model, using melanoma cells that weakly expressed
OPN, the number of metastases at a variety of sites was suppressed
in the OPN-deficient mice as compared to those in WT (Nemoto
et al, 2001). Taken together, these results suggest that the role of
OPN in tumour development is complex and may be affected by a
variety of parameters, including tumour type and experimental
system: in turn, these parameters may reflect a role of the tumour
microenvironment in determining the effects of OPN. Since OPN
can be produced by many cell types in a tumour microenviron-
ment, including tumour cells themselves, activated immune cells,
remodelling vasculature, and bone cells, in the case of tumours
growing in bone; it may be that OPN from different sources
mediate different effects. For instance, OPN originating from
different cellular sources may have differential post-translational
modifications and/or may be differentially cleaved, suggesting
possible differential functions.
OPN expression in human tumours: potential utility as a
tumour marker
Following the identification of OPN as a phosphoprotein secreted
by transformed cells in culture (Senger et al, 1979), OPN mRNA
and protein were shown in histological sections of several types of
human cancer to be elevated relative to normal tissue (Brown et al,
1994). In this study, OPN RNA was found to be produced primarily
by tumour-associated macrophages rather than tumour cells
themselves. However, Tuck et al (1998), examined a series of
tumours from 154 lymph node-negative breast cancer patients.
Osteopontin RNA and protein were detected in both tumour cells
and infiltrating inflammatory cells: host immune cells were
positive for OPN protein in 70% of tumours, while only 26% of
tumours were positive for OPN immunostaining in the breast
tumour cells themselves. Interestingly, OPN positivity specifically
in tumour cells correlated with patient survival, while OPN in host
cells was too common to provide prognostic information. This
study supported the idea that multiple cell types in a tumour
microenvironment may produce OPN, including tumour cells and
host infiltrating cells, but that these sources of OPN may be
functionally distinct.
OPN has been detected in a growing number of human tumour
types, including lung, breast, prostate, gastric, oesophageal,
ovarian and glioma, by immunohistochemistry on tumour tissue
sections, quantification of OPN RNA from tumour tissue or in
expression array studies from tumour tissues (reviews: Furger et al,
2001; Tuck and Chambers, 2001). In some of these studies, clinical
and patient outcome data are available, enabling OPN expression
to be assessed as a potential marker of tumour progression. In a
series of 25 lung tumour specimens, OPN protein and RNA were
elevated in tumour tissue, relative to normal lung tissue, and OPN
immunopositivity was statistically significantly associated with
patient survival (Chambers et al, 1996). In the study described
above by Tuck et al (1998), examining tumours from lymph node-
negative breast cancer patients, OPN protein detected specifically
in the tumour cells in breast tumours correlated significantly with
disease free- and overall survival in these patients. Consistent with
this finding is a case report of bilateral mammary carcinomas
(Tuck et al, 1997), in which OPN tumour cell immunopositivity, as
well as p53 immunopositivity, were associated with the tumour
that recurred locally and progressed to form metastases in the liver
and bone. In a recent study of 68 breast tissue samples from
primary tumours, nodal metastases, fibroadenomas and normal
tissue, OPN protein and RNA were elevated in malignant vs
benign/normal tissues, although no differences in RNA levels
quantified by RT–PCR were found when tumours with vs without
metastases were compared (Wang-Rodriguez et al, 2003). Finally,
OPN immunopositivity in a group of 333 breast cancer patients
demonstrated a negative correlation with survival (Rudland et al,
2002). Given the common finding of OPN in nontumour
(infiltrating) cells, reported by Tuck et al (1998), it may be that
OPN protein detection, when limited to quantification from only
the tumour cells, may provide more useful predictive information
than RNA levels quantified from tumour tissue, at least for breast
cancer.
In contrast, in a study of a series of 240 hepatocellular
carcinomas, elevated OPN RNA levels were associated with high
grade, late stage and early recurrence, which are all associated with
poor patient prognosis (Pan et al, 2003). In an expression array
study of 60 colorectal tumours, representing a range of stages from
adenomas, Astler Collier stages B, C and D, and liver metastases,
OPN was identified as the lead marker that was most consistently
upregulated with tumour progression (Agrawal et al, 2002).
Osteopontin RNA and protein in tumour tissue have also been
shown to have a potential prognostic value in ovarian cancer, with
OPN levels being higher in tumour tissue than in normal or benign
tissue (Kim et al, 2002). Recently, Coppola et al (2004) used tissue
arrays to assess OPN protein levels in 350 tumours from 23 body
sites compared with 113 normal tissues. In that study, OPN was
found to be elevated in tumours, relative to normal tissues.
Osteopontin also was found to correlate significantly overall with
tumour stage, when considering all tumour sites and to correlate
with tumour stage for several sites individually, including bladder,
colon, kidney, larynx, mouth and salivary gland (Coppola et al,
2004).
OPN RNA and protein thus have been found to be over-
expressed in a number of human tumour types, relative to normal
tissue. This is perhaps not surprising, since OPN expression can be
induced by the ras oncogene (Denhardt et al, 2003) and the ras
pathway is activated either directly or indirectly in a high
proportion of human tumours (Bos, 1989; Clark and Der, 1995).
In some cases, OPN overexpression has been shown to be
associated directly with poor patient prognosis or with other
indicators of poor prognosis. There also is some suggestion that
Role of osteopontin in tumour progression
SR Rittling and AF Chambers
1878
British Journal of Cancer (2004) 90(10), 1877–1881 & 2004 Cancer Research UKOPN from different sources may have different prognostic value.
As noted above, Tuck et al (1998) found that OPN immunopo-
sitivity within breast tumour cells was associated with poor patient
survival, whereas OPN in infiltrating host cells in the tumours was
common and not associated with survival. It should be noted that
OPN is not specific to tumours, but is expressed by a number of
other tissues, under normal or pathological conditions, and this
must be considered in any studies assessing the utility of OPN as a
marker of prognosis in cancer. While further studies, using large
numbers of samples associated with clinical and patient outcome
data, will be needed to determine the prognostic value of OPN in
specific human cancers, studies to date support the hypothesis that
OPN detected within tumour cells has a potential utility as a
prognostic marker.
OPN expression in human tumours: potential utility as a
blood marker
In addition to being present in tumours and some normal tissues,
OPN also is found in bodily fluids. By Western blotting, OPN
blood levels appeared to be elevated in a small number of patients
with various cancers (Senger et al, 1988). Bautista et al (1996)
developed the first ELISA able to quantify OPN levels in blood
plasma and using this assay they measured baseline levels in a
series of normal women. Singhal et al (1997) then used this ELISA
to quantify OPN plasma levels in 70 women with metastatic breast
cancer compared to healthy women and women on well follow-up
for cancer. Osteopontin plasma levels were significantly elevated in
women with metastatic breast cancer, relative to either control
group (Po0.001). Furthermore, elevated OPN levels were sig-
nificantly associated with patient survival as well as with increased
numbers of metastatic sites.
A number of recent studies have confirmed these initial findings
and have extended them to other cancer types. Fedarko et al (2001)
measured OPN serum levels in patients with breast, colon, lung or
prostate cancer compared with normal serum, and found elevated
OPN levels in all tumour types except colon cancer. No clinical or
outcome data on the patients in this study were available. In a
prospective study, Hotte et al (2002) examined OPN plasma levels
in a series of 100 men with hormone refractory prostate cancer.
Osteopontin levels were found to correlate negatively and
independently with patient survival (P¼0.029). In these patients
there also was a statistically significant correlation between OPN
levels and the presence of metastases to bone (P¼0.024). Plasma
OPN also has been examined as a potential prognostic marker in
head and neck cancers (Le et al, 2003). Osteopontin levels were
elevated in these patients when compared with normal control
samples: these levels correlated with relapse-free and overall
survival in the patients. Finally, Kim et al (2002) measured OPN in
plasma samples from 144 women being assessed for possible
ovarian cancer compared with 107 normal control samples. Plasma
OPN levels were elevated in the group of 51 women with ovarian
cancer (Po0.001) compared with healthy women or women with
benign ovarian disease.
Taken together, this growing list of studies suggests that OPN
blood levels have a potential as a prognostic or diagnostic marker
in prostate, breast, head and neck, and likely other cancers. It
should be noted, however, that OPN is unlikely to be a blood
marker that is specific to cancer. Osteopontin levels are elevated in
other conditions including sepsis, kidney disease and cardiovas-
cular disease, and OPN blood levels in these conditions has not
been thoroughly evaluated. Even in patients known to have cancer,
OPN blood levels may be elevated due to noncancer causes, which
must be considered in evaluating the results. Clearly, larger
prospective trials will be needed to assess the ability of plasma
OPN to provide prognostic information or indications of treatment
responses.
Mechanism of action of OPN in regulating tumour growth
The mechanisms by which OPN may enhance malignancy are still
unclear. However, several mechanisms have been suggested
through studies in cultured cells. First, the ability of cells to grow
in soft agar or in the absence of adhesion is closely associated with
tumorigenicity. Several lines of evidence suggest that OPN
enhances growth of transformed cells in suspension, including
experiments with inducible OPN (Wu et al, 2000) as well as in JB6
cells, in which the addition of OPN to cells increases their ability to
grow in soft agar (Chang et al. 2003). Secondly, the ability of cells
to migrate may be directly tied to their tumorigenicity and OPN
clearly participates in pathways regulating migration in diverse cell
types including osteoclasts, fibroblasts, macrophages and tumour
cells (Tuck et al, 2000). Interestingly, in macrophages, OPN
regulates migration toward some chemokines but not others,
suggesting that the protein may function in a subset of migratory
pathways (Zhu et al, 2003): perhaps, this observation may help to
explain some of the diverse effects of OPN in different tumour
systems. Invasiveness is clearly related to migration, but not only
do cells need to be motile to invade, they also need to degrade the
extracellular matrix. Several studies suggest that OPN increases
invasiveness by inducing proteinases, particularly uPA (Tuck et al,
1999; Das et al, 2003). Finally, recent experiments suggest that
OPN acts in concert with several growth factors, including HGF
(Medico et al, 2001) and EGF (Tuck et al, 2003), to induce
malignant properties. Again, these observations suggest that OPN
may have different effects in different tumours depending on the
growth factor milieu.
OPN has also been implicated in the process of angiogenesis,
particularly as it is a high-affinity ligand for the avb3 integrin,
which is highly expressed on some endothelial cells. Signalling
through the avb3 is critical for endothelial cell survival and indeed
OPN when immobilised on a surface enhances survival of
endothelial cells (Scatena et al, 1998). While there have been
sporadic reports of OPN functioning to promote angiogenesis,
firm evidence linking the protein to vessel development in the in
vivo systems has been scarce. Recent data demonstrating that OPN
accelerates blood vessel formation in matrigel and chorioallantoic
membrane assays in the presence of FGF-2, however, suggest that
OPN may act in concert with other proangiogenic molecules to
enhance angiogenesis (Leali et al, 2003). Again, these results
underscore the idea that the exact function of OPN in any given
situation may be determined by interactions with other factors in
the microenvironment.
CONCLUSIONS
Studies in vitro and in animal models of cancer have clearly
indicated that OPN can function to regulate tumour growth and
progression. Numerous reports of elevated OPN expression in
human cancers support the idea that OPN should be considered as
a potential prognostic marker for a variety of human cancers.
There is clearly a need for larger, well-designed prospective studies
to evaluate definitively the utility of OPN as a tumour as well as
blood marker of tumour progression. These experiments should
take into account that multiple cell types can express OPN and that
blood levels of the protein thus may be elevated due to noncancer
causes. Finally, studies testing the prognostic importance of
coexpression of OPN and other growth factors could yield
important new mechanisms of evaluating human cancers.
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